Results 101 to 110 of about 115,857 (253)

Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests

British Journal of Haematology, EarlyView.
Summary Haematological malignancies are rare in primary care and are hard to predict. Existing prediction models often require a specific working diagnosis and are based on extensive clinical information, access to which may be limited at initial work‐up in primary care.
Mathilde Egelund Christensen, Michael Charles Sachs, William Grant Dunn, Gustav Jonzon, Margit Kriegbaum, Bent Struer Lind, Jan Samuelsson, Kirsten Groenbaek, George Vassiliou, Christen Lykkegaard Andersen   +9 more
wiley   +1 more source

DP133 | CIP2A IS IMPLICATED IN RUXOLITINIB RESISTANCE IN MYELOFIBROSIS

Haematologica
Although ruxolitinib (Ruxo) is the standard of care for patients (pts) with myelofibrosis (MF), therapeutic resistance develops in approximately 50% within 3-5 years, posing a clinical challenge.
M. Balliu, M. Vannucchi, M.C. Siciliano, M. Lomi, C. Basile, P. Guglielmelli, A.M. Vannucchi   +6 more
doaj  

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms

Haematologica, 2010
Background Aberrant activation of tyrosine kinases, caused by either mutation or gene fusion, is of major importance for the development of many hematologic malignancies, particularly myeloproliferative neoplasms.
Thomas Ernst, Andrew Chase, Katerina Zoi, Katherine Waghorn, Claire Hidalgo-Curtis, Joannah Score, Amy Jones, Francis Grand, Andreas Reiter, Andreas Hochhaus, Nicholas C.P. Cross   +10 more
doaj   +1 more source

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 [PDF]

, 2013
Item does not contain fulltextBACKGROUND: Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms with nonmutated JAK2 is obscure, and the diagnosis of
Avezov, E, Hinton, J., Kollmann, K., Cross, N.CP., Avezov, E., Kollmann, Karoline, Mudie, Laura, Cross, N.C.P., Aziz, A., Papaemmanuil, E., Martincorena, Inigo, Goudie, Calum T., Nangalia, Jyoti, Harrison, C.N., Maddison, Mark, Jones, A.V., Teague, Jon W., Orchard, Kim, Ortmann, Christina A., Bloxham, David, Li, J., Bianchi, Michele, Huntly, B.JP., Massie, C.E., Ron, D., Cross, Nicholas C. P., Van Loo, P., McLaren, S., Tauro, S., Tarpey, Patrick, Vannucchi, A.M., Kent, DG, Tarpey, P., Baxter, E.J., Harrison, Claire N., Nangalia, J, Butler, Adam P., Guglielmelli, Paola, Loo, P. Van, Bianchi, M., Hinton, Jonathan, Loughran, Stephen J., Kent, D.G., Li, Juan, Kent, David G., Raine, K., Nice, F.L., Massie, CE, Martincorena, I., Harding, H.P., Huntly, B.J.P., Godfrey, A.L., Orchard, K., Bloxham, D., Jones, David R., Baxter, E. Joanna, Green, A. R., Van Loo, Peter, Kollmann, K, Avezov, Edward, Aziz, Athar, Ron, David, Silber, Yvonne, Greaves, M., Campbell, P.J., O'Meara, Sarah, Hill, K., Nangalia, J., Huntly, B.J., Robinson, B., Robinson, Ben, Du, M.-Q., Tauro, Sudhir, Aziz, A; et al., Maclean, Cathy, Du, M.Q., Huntly, Brian J. P., Hill, Kate, Nice, FL, Keohane, Clodagh, Mudie, L., Campbell, Peter J., Dimitropoulou, Danai, Cross, N.C., Silber, Y., Du, Ming-Qing, Godfrey, Anna L., Fitzpatrick, John D., Harding, Heather P., Green, Anthony R., Maclean, C., Gundem, Gunes, Li, J, Jones, D.R., Fitzpatrick, J.D., Teague, J.W., Wedge, D.C.; id_orcid, O'Meara, S., Baxter, EJ, Gundem, G, Keohane, C., Guglielmelli, P., Loughran, S.J., Bowen, David, McLaren, Stuart, Green, A.R., Greaves, Mel, Wedge, David C., Massie, Charles E., Gundem, G., Maddison, M., Du, M-Q., Dimitropoulou, D., Papaemmanuil, Elli, Wedge, DC, Wedge, D.C., Goudie, C.T., Raine, Keiran, Ortmann, C.A., Jones, Amy V., Nice, Francesca L., Bowen, D., Butler, A.P., Vannucchi, Alessandro M.   +123 more
core   +1 more source

Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis

, 2021
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme ...
Trotti C, Ferretti VV, Arcaini L, Pietra D, Borsani O, Casetti IC, Astori C, Rumi E., Vanni D, Sant'Antonio E   +9 more
core   +1 more source

Algorithms in Allergy: Diagnosis of Hypereosinophilic Syndromes, 2026 Update

Allergy, EarlyView.
Guillaume Lefèvre, Florence Roufosse, Giacomo Emmi, Andreas Reiter, Emmanuel Ledoult, Jean‐Emmanuel Kahn   +5 more
wiley   +1 more source

C019 | INIBITION OF PI3KΔ BY ROGINOLISIB (IOA-244) AS A POTENTIAL THERAPEUTIC STRATEGY FOR MYELOFIBROSIS

Haematologica
Due to its clonal stem cell origins and the resulting dysregulation of the JAK/STAT pathway, myelofibrosis (MF) treatment has undergone a paradigm shift with the development of JAK-inhibitors.
M. Balliu, G. Di Conza, M. Lahn, P. Guglielmelli, A.M. Vannucchi   +4 more
doaj  

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

Haematologica, 2012
We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger, Ulrike Bacher, Christiane Eder, Frank Dicker, Tamara Alpermann, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +9 more
doaj   +1 more source

Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML‐IPC‐AURAML consortium

British Journal of Haematology, EarlyView.
Summary Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)‐dose ...
Pierre‐Yves Dumas, Sarah Bertoli, Emilie Bérard, Clémence Santana, Maël Heiblig, Thibaut Leguay, Suzanne Tavitian, Estelle Borgne, Anne‐Charlotte de Grande, Audrey Sarry, Ziyad Acheaibi, Laetitia Largeaud, Morgane Sighieri, Emilie Klein, Emmanuelle Tavernier, Marie‐Anne Hospital, Martin Carré, Gaspar Aspas Requena, Anne Banos, Norbert Vey, Arnaud Pigneux, Christian Récher, Sylvain Garciaz   +22 more
wiley   +1 more source

P211 | NEUTROPHIL-TO-LYMPHOCYTES RATIOS CAN PREDICT OUTCOMES AND TREATMENT RESPONSE IN MYELOFIBROSIS PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY

Haematologica
Background: Myelofibrosis (MF) is the most symptomatic form of MPN and carries the worst outcome. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII) and systemic inflammation response index
G. Capecchi, V. Boldrini, G. Coltro, G. G. Loscocco, L. Fagiolo, G. Borgi, C. Matteoli, T. Barbui, A.M. Vannucchi, P. Guglielmelli   +9 more
doaj